Triple negative breast carcinoma (TNBC) represents approximately 10–20% of all breast cancers and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression [1,2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.